Atai Life Sciences raised €131M in a Series D+ round in Mar 2021. The company is based in Munich, Germany. Investors in the round: Apeiron Investment Group, Thiel Capital, Woodline Partners. Data as of 6 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
